<DOC>
	<DOCNO>NCT00060255</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy autologous stem cell transplantation autologous bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well eight different high-dose chemotherapy regimen without total-body irradiation follow autologous stem cell transplantation autologous bone marrow transplantation work treat patient hematologic malignancy solid tumor .</brief_summary>
	<brief_title>High-Dose Chemotherapy , Total-Body Irradiation , Autologous Stem Cell Transplantation Bone Marrow Transplantation Treating Patients With Hematologic Cancer Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine morbidity , mortality , overall outcome patient hematologic malignancy , breast cancer , chemosensitive solid tumor treat disease-specific dose-intensive conditioning regimen autologous peripheral blood bone marrow transplantation . OUTLINE : Patients stratify accord risk group ( standard vs high ) . Standard risk include acute leukemia first relapse second remission ; lymphoma respond first relapse second remission ; breast cancer risk recurrence . High risk include others . Patients receive specific conditioning regimen accord diagnosis outline . Conditioning - Regimen A ( standard risk non-Hodgkin 's lymphoma 60 year age ) -Etoposide , cyclophosphamide , total body irradiation ( TBI ) ( VCT ) : Patients receive etoposide IV continuously 26 hour begin day -5 cyclophosphamide IV 2 hour day -4 . Patients undergo TBI day -3 -1 . - Regimen B ( risk Hodgkin 's lymphoma 60 year age ) -Cyclophosphamide , carmustine , etoposide ( CBV ) : Patients receive etoposide IV continuously 34 hour begin day -8 ; cyclophosphamide IV 2 hour day -7 -4 ; carmustine IV 2 hour day -3 . - Regimen C ( risk patient prior exposure high-dose etoposide cyclophosphamide 60 year age ) -Melphalan TBI ( MEL/TBI ) : Patients receive melphalan IV 30 minute day -4 . Patients undergo TBI day -3 -1 . - Regimen D ( multiple myeloma amyloidosis ) -Melphalan ( MEL ) : Patients receive melphalan IV 30 minute day -2 . - Regimen E ( patient unable receive TBI ) -Busulfan cyclophosphamide : Patients receive oral busulfan ( busulfan IV 2 hour ) day -7 -4 cyclophosphamide IV 2 hour day -3 -2 . - Regimen F ( risk breast cancer ) -Cyclophosphamide , carboplatin , thiotepa ( STAMP V ) : Patients receive cyclophosphamide IV 24 hour , carboplatin IV 24 hour , thiotepa IV 24 hour day -7 -4 . - Regimen G ( solid tumor breast testicular cancer ) -Thiotepa carboplatin ( TT/CARBO ) : Patients receive thiotepa IV 2 hour day -6 -5 carboplatin IV continuously 96 hour begin day -6 . - Regimen H ( recurrent primary progressive testicular cancer ) -Etoposide carboplatin ( VP/CARBO ) : Patients receive etoposide IV 2 hour carboplatin IV 30 minute day -6 -4 . Stem Cell Infusion - In regimen , patient undergo autologous stem cell infusion day 0 . Treatment continue absence unacceptable toxicity . PROJECTED ACCRUAL : Approximately 450 patient ( 50 patient [ 25 per stratum ] per regimen ) accrue study within 10 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hematologic solid tumor malignancy , include follow : Acute myeloid leukemia First remission eligible allogeneic transplantation ; recurrent disease combination chemotherapy least 1 standard regimen ; second remission Not eligible protocol CLB9620 CLB9621 Acute lymphoblastic leukemia First complete remission without appropriate allogeneic donor Chronic myelogenous leukemia Chronic , accelerate , blast phase Lymphoproliferative diseases* Chronic lymphocytic leukemia Multiple myeloma Waldenstrom 's macroglobulinemia Lowgrade nonHodgkin 's lymphoma ( NHL ) NOTE : *Recurrent persistent , symptomatic disease firstline chemotherapy , subsequently Amyloidosis Primary previously treat disease NHL ( intermediate highgrade ) Resistant recurrent disease combination chemotherapy least 1 standard regimen First remission lymphoblastic small , noncleaved cell lymphoma high risk relapse CNS disease OR bone marrow disease lactic dehydrogenase great 300 IU/L Hodgkin 's lymphoma Resistant recurrent disease combination chemotherapy least 1 standard regimen Solid tumor Highrisk metastatic breast cancer Testicular cancer relapse OR primary progressive disease respond salvage therapy Other solid tumor recur conventional therapy OR high risk relapse , demonstrate chemosensitivity Less 10 % marrow tumor present histologically ( maximum 15 % involvement allow purge ) Allogeneic marrow transplantation possible desirable follow reason : Over 60 year age No compatible donor identify Estimated risk graftversushost disease complication great risk recurrence autologous bone marrow transplantation Patients disease progression site prior radiotherapy ( 4,000 cGy ) eligible total body irradiation ( TBI ) regimens Hormone receptor status : Not specify NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 4 ( patient 60 year age eligible TBI ) Sex Male female Menopausal status Not specify Performance status Karnofsky 70100 % Life expectancy More 2 month Hematopoietic WBC great 3,000/mm^3* Polymorphonuclear leukocyte count great 1,500/mm^3* Platelet count great 75,000/mm^3* Marrow cellularity great 20 % * No marrow fibrosis* NOTE : *Before marrow storage Hepatic Bilirubin less 3 time normal Alkaline phosphatase less 3 time normal AST le 3 time normal Hepatitis status know Renal Creatinine clearance least 50 mL/min ( required patient amyloidosis multiple myeloma ) Cardiovascular Ventricular ejection fraction least 50 % radionuclide ventriculogram echocardiogram No myocardial infarction within past 6 month No congestive heart failure No symptomatic angina No lifethreatening arrhythmia hypertension Pulmonary DLCO DLVA least 50 % predict ( DLCO must correct hemoglobin and/or alveolar ventilation ) Other Not pregnant HIV negative Cytomegalovirus status know No active bacterial , viral , fungal infection No active peptic ulcer disease No uncontrolled diabetes mellitus No serious organ dysfunction unless cause underlying disease No serious medical psychiatric illness would preclude give informed consent comply study requirement PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics No prior cumulative nitrosourea dose great 600 mg/m^2 No prior cumulative bleomycin dose great 150 units/m^2 No prior cumulative doxorubicin dose great 450 mg/m^2 No prior cumulative daunorubicin dose great 600 mg/m^2 Patients prior highdose cyclophosphamide ( great 150 mg/kg per cycle ) highdose etoposide ( great 2,400 mg/m^2 per cycle ) eligible etoposide/cyclophosphamide/TBI condition regimen Endocrine therapy Not specify Radiotherapy See Disease Characteristics More 3 week since prior radiotherapy ( blood stem cell harvest ) Prior cumulative dos radiotherapy must exceed follow : Spine/spinal cord : 4,000 cGy Mediastinum : 4,000 cGy Heart : 4,000 cGy Kidney ( whole ) : 1,500 cGy Small bowel : 4,000 cGy Brain : 4,000 cGy Liver ( whole ) : 2,000 cGy Lungs ( whole ) : 1,500 cGy Bone : 5,000 cGy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>